StockWireNews

Wednesday AM Complete Update On Nasdaq Profile (MYNZ)

December 7th

Greetings Readers,

MYNZ needs top spot on your watch-list again today. Here's why.

Tuesday, MYNZ closed green, up approximately 7% from Monday's close.

But why is that special? It's special because the Dow and Nasdaq took a beating yesterday.

On top of that, it has some game-changing news that has only been out for just over 24 hours. As it continues to circulate, MYNZ could be in for a ton of added exposure.

Check out the news here: Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study

Furthermore, MYNZ closed above several lines of potential support including its:

• 5-Day Simple Moving Average (SMA)
• 20-Day SMA
• 50-Day SMA
• 5-Day Exponential Moving Average (EMA)
• 13-Day EMA

If potential support keeps growing at these levels, it could act as the building blocks for a continued vertical run near term.

Read my initial MYNZ report below and get this Nasdaq past champ back on radar quickly.

-----

Tuesday's opening bell is nearly here. Here's what you need to know.

I've been tracking a specific Nasdaq past champ that requires full attention ASAP.

In fact, this isn't just a 1X past champ, it's a 2X past champ.

When I delivered this idea to your inboxes originally, it went absolutely bonkers.

Running an insane 200+% (approx.) in the short term, it turned into a stunning multi-dollar mover.

With its breakout potential starting to grow again, I brought it back to attention only to watch it pop another 30+% in a very little period of time.

Now, with several key potential catalysts including a low float, huge revenue news, a recent corporate update, and a November press release regarding the U.S. extension of a prefeasibility study, it needs to own the top spot on your watch-list immediately.

Right now, there is only one profile to be watching closely at Tuesday, December 6th's opening bell:

*Mainz Biomed B.V. (MYNZ)*

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.

And right now, 5 potential catalysts could provide this profile with a breakout spark near term. Here's what to know:

No. 1 - Low Float Volatility Could Be On Display Daily

No. 2 - Two Different Analysts Provide An Average Price Target Of $20

No. 3 - Company Announces eAArly DETECT, U.S. Extension Of Key Prefeasibility Study

No. 4 - Q3 Update Paints The Picture Of A Company Moving In The Right Direction

No. 5 - Key Company Highlights (Including Revenue Growth) Provide A Bullish Future Outlook

But more on those in a second...

About MYNZ: Early Identification Of Cancer Saves Lives

Mainz BioMed – founded in Mainz, Germany and aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere.

Developing market-ready molecular in-vitro diagnostics tests since 2010.

Their goal is to place effective solutions where they need to be… In your hands.

A Blockbuster Early Detection Test for Colorectal Cancer

Significant Impact: Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%.

Revenue Generating: ColoAlert is CE-IVD marked and is approved for sale in Europe. European sales will provide near-term revenue potential, while we prepare our entry into the US market. Process launched in 1Q2022.

U.S. Markets: We have begun the FDA process. Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to market potential of over 52Mn tests per year.

Ease of Use: Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity (which is expected to be increased for the FDA product). Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy.

Experienced Management: Seasoned and experienced management, board & advisors with particular skill sets in commercializing and monetizing medical diagnostics at some of the largest medical companies in the world.

Attractive Valuation: They believe their current valuation holds tremendous upside.

ColoAlert - Simple, Fast, Accurate and Non-Invasive

• A PCR-based CRC early detection stool test
• Non-invasive, no preparation or sedation, no time off work
• 98% patient satisfaction – Easy product to use
• Designed to offer affordable CRC screening solutions

Grab more key details and sources here.

-----

Mentioned above, MYNZ has 5 potential catalysts that could provide it with a near term breakout spark. Check them out:

No. 1 MYNZ Potential Catalyst - Low Float Volatility Could Be On Display Daily

According to the Yahoo Finance website, MYNZ has a low float.

The website reports this profile to have approximately 10.56Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more 2022 positive company news help provide a near term spark?

-----

No. 2 MYNZ Potential Catalyst - Two Different Analysts Provide An Average Price Target Of $20

Wow. Over at TipRanks, I found this:

From Monday's closing valuation, MYNZ is displaying a ton of potential upside to this $20 average target.

In fact, that's over 125+% potential upside.

Now, I'm not saying this profile is going to surge to $20 this week, but over the past 52-week period it has a high of $30.

Even a partial return to those levels would mean a major move from MYNZ from current trading areas.

-----

No. 3 MYNZ Potential Catalyst - Company Announces
eAArly DETECT, U.S. Extension Of Key Prefeasibility Study

Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert

• eAArly DETECT expected to complete enrollment in Q1 2023 with results in 1H 2023
• Enhances ColoFuture’s demographic profile and expedites data read-out timeline
• Potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to colorectal cancer (CRC)

BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the initiation of eAArly DETECT, its U.S. extension of ColoFuture, the Company’s European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert, Mainz’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) being commercialized across Europe and in select international territories. ColoFuture/eAArly DETECT are multi-center studies assessing the potential of these biomarkers to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC.

“We are excited by the opp. to expand the ColoFuture study to the U.S. as it enables us to accelerate the timeline to evaluate the potential of these biomarkers to be incorporated into our U.S. pivotal study, which is on track to initiate later this year,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The combinatory U.S. and European studies represent groundbreaking work in the field, as the potential inclusion of advanced adenomas in ColoAlert’s technical profile will represent a transformational advancement in self-administered CRC screening.”

...

Read the full article here.

-----

No. 4 MYNZ Potential Catalyst - Q3 Update Paints The Picture Of A Company Moving In The Right Direction

Mainz Biomed Provides Third Quarter 2022 Update

BERKELEY, Calif. and MAINZ, Germany, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer today provided an update on accomplishments during the third quarter which ended September 30, 2022.

Key Highlights and Recent Developments

• Expanded European and international commercial franchise for ColoAlert, the Company’s highly efficacious and easy-to-use DNA-based detection test for colorectal cancer (CRC) via the launch of direct-to-consumer programs in Italy and the United Arab Emirates (UAE)
• Maintained execution timeline for ColoFuture, an international multi-center clinical study assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert - on track to report results in 1H 2023
• Continued final preparations for U.S. pivotal clinical study evaluating next-generation CRC test - on track to commence in Q4 2022
• Formed a Medical Advisory Board of renowned scientific oncology experts to support the advancement of product portfolio candidates and assist with pipeline enhancement opp's
• Bolstered leadership team by appointing two highly accomplished healthcare executives to the Board of Directors

“The major emphasis for the past quarter was to continue executing our commercial strategy for ColoAlert across Europe and in select international territories while making final preparations to launch our U.S. pivotal clinical study designed to evaluate a next-generation self-administered diagnostic test for CRC,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “We head into the final months of 2022 with great momentum across corporate and product development fronts, and I look forward to keeping our shareholders and interested parties posted on progress.”

...

Read the full article here.

-----

No. 5 MYNZ Potential Catalyst - Key Company Highlights (Including Revenue Growth) Provide A Bullish Future Outlook

Mainz Biomed Reports First Half 2022 Fi-nan-cial Results

• 127% year-over-year increase in ColoAlert revenue
• Mid-year cash balance of $26Mn

BERKELEY, Calif. and MAINZ, Germany, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the first half of the fiscal year ended June 30, 2022.

Key Corporate & Product Development Highlights

• Accelerated international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC)
• Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial Officer
• Established partnership with Dante Labs to market ColoAlert in Italy and the United Arab Emirates
• Initiated and enrolled the first patient in an international clinical study (ColoFuture) evaluating the integration of novel mRNA biomarkers into ColoAlert – potentially upgrading its technical profile to achieve “gold standard” status for CRC at-home testing
• Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022
• Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer
• Executed a $25.8Mn (gross) public follow-on offering
• Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization

“At the outset of 2022, we established ambitious commercial and product development objectives for the year, mostly around our flagship product ColoAlert. I’m pleased to report that we achieved all of our corporate growth goals for the first half period,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The Company is fi-nan-cially well positioned to maintain momentum as ColoAlert continues to gain impressive commercial traction across Europe and select international territories, and as we ramp up to launch its U.S. pivotal clinical trial by the end of the year.”

...

Read the full article here.

-----

MYNZ Recap - 5 Must-Know Potential Catalyst For This Nasdaq Past Champ

No. 1 - Low Float Volatility Could Be On Display Daily

No. 2 - Two Different Analysts Provide An Average Price Target Of $20

No. 3 - Company Announces eAArly DETECT, U.S. Extension Of Key Prefeasibility Study

No. 4 - Q3 Update Paints The Picture Of A Company Moving In The Right Direction

No. 5 - Key Company Highlights (Including Revenue Growth) Provide A Bullish Future Outlook

-----

Coverage is officially reinitiated on MYNZ. When time permits, do this:

Get MYNZ on your radar now.

Sincerely,

Kai Parker

StockWireNews

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)